Baseline patient and disease characteristics of the 3920 analysed patients enrolled in the COMORA Study
| Variable | Results | |
|---|---|---|
| Global results | Extremes (countries) | |
| Number | 3920 | From 30 (Uruguay) to 411 (France) |
| Female gender (%) | 81.7 | From 66 (Netherlands) to 91 (Venezuela) |
| Age (years), mean±SD | 56±13 | From 48 (Morocco/Egypt) to 63 (Japan) |
| Smoking status (% current smokers) | 13.2 | From 0.9 (Morocco) to 48 (Austria) |
| Educational level (% university or graduate school) | 24.5 | From 5.3 (Italy) to 75 (Netherlands) |
| Marital status (% married) | 69.7 | From 50 (Venezuela) to 86 (Netherlands) |
| BMI (% overweight or obese) | 50.7 | From 0 (Netherlands) to 69 (USA) |
| Work status (% currently employed) | 31.4 | From 16 (Morocco) to 46 (USA) |
| Disease duration (years), mean±SD | 9.6±8.7 | From 7 (Morocco) to 14 (France) |
| DAS28–ESR, mean±SD | 3.7±1.6 | From 2.6 (Netherlands) to 5.3 ( Egypt) |
| HAQ, mean±SD | 1.0±0.7 | From 0.7 (Taiwan) to 1.5 (Morocco) |
| Prednisone (% currently taking) | 54.3 | From 9 (UK) to 82 (Morocco) |
| NSAID use (% having taken dose during previous 3 months) | 55.2 | From 25 (Morocco) to 94 (Taiwan) |
| MTX (% ever treated) | 88.6 | From 79 (Italy) to 98 (UK) |
| Any biological therapy (% ever treated) | 38.9 | From 3 (Uruguay) to 77 (UK) |
BMI, body mass index; DAS28–ESR, Disease Activity Score using 28 joints–erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.